Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transducin beta-like protein 2 (TBL2) is a member of the beta-transducin protein family encoded by the TBL2 gene on chromosome 7q11.23[1][6]. The protein is possibly involved in intracellular signaling and has roles in the endoplasmic reticulum (ER) stress response, particularly the unfolded protein response[2]. Genetic deletion of TBL2 has been implicated in Williams-Beuren syndrome, a neurodevelopmental disorder caused by deletions at chromosome region 7q11.23[1]. TBL2 has also been identified as a potential driver gene in certain cancers, such as lung adenocarcinoma, where it may promote tumor growth by adapting to ER stress[5]. There are no established drugs reported to specifically target TBL2, and its direct therapeutic or biomarker utility remains unclear.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transducin beta-like protein 2 (TBL2).